$0.24317 38.87%
VET · 2w

J&J Vaccine Manufacturing Error Affects 15 Million Doses - Another situation that could have been avoided/detected much earlier if they been using Vechain

A manufacturing error at a plant involved in Covid-19 vaccine production affected 15 million doses worth of an ingredient for Johnson & Johnson’s vaccine, according to two people familiar with the matter, though the company downplayed the situation and said it met its most recent vaccine delivery target.

The issue, which occurred recently at an Emergent BioSolutions Inc. facility in Baltimore, isn’t expected to change President Joe Biden’s expectation that the U.S. will have enough vaccine for all adults in May, the people said.

None of the doses produced and shipped so far in the U.S. have come from that plant, which isn’t authorized yet, two administration officials said, speaking on condition of anonymity.

In a statement, J&J said a batch of drug substance failed its quality test.

Workers inside a lab at Emergent Biosolutions in Baltimore on Feb. 8. Photographer: Michael Robinson Chavez/The Washington Post/Getty Images More from

Manufacturing problems at the plant were first reported by the New York Times Wednesday. Workers there accidentally conflated ingredients belonging to the J&J vaccine and another manufactured on the premises for AstraZeneca Plc, according to the report. Astra didn’t immediately return calls for comment.

How the issue may affect the U.S. vaccine rollout is unclear. J&J, as of now, has produced by far the smallest supply of the U.S.-authorized Covid-19 vaccines. The two other vaccine producers, Pfizer Inc. and Moderna Inc., met their first quarter targets of 120 million doses and 100 million doses, respectively. Those vaccines require a two-dose regimen.

“This quality control process identified one batch of drug substance that did not meet quality standards at Emer...

Continue on
Recent news
VET +38.87% · · 15h


Stay tuned!— VeChain Foundation (@vechainofficial) April 16, 2021